$26.90
5.98%
Nasdaq, Apr 25, 09:50 pm CET
ISIN
US38870X1046
Symbol
LENZ
Sector
Industry

Graphite Bio Inc Stock News

Positive
Seeking Alpha
20 days ago
LENZ Therapeutics' LNZ100 for presbyopia is in an advanced approval phase, targeting a $3B+ market, with potential U.S. launch in 2025. With $209.1M in cash and no debt, LENZ is expected to reach positive cash flow in 2027-2028. A base-case Fair Value estimate is $42.55, indicating a 101% potential upside; while in an optimistic scenario with international expansion, the Fair Value estimate is ...
Positive
Seeking Alpha
about one month ago
LENZ Therapeutics, Inc.'s LNZ100 eye drop shows promising results for presbyopia, with strong phase 3 data and potential FDA approval by August 2025. LNZ100 demonstrated superior efficacy compared to AbbVie's Vuity, with a broad patient range and rapid onset of treatment effect. Survey data indicates high interest among eye care professionals, with 82% likely to prescribe LNZ100 if approved, ta...
Neutral
Seeking Alpha
about one month ago
LENZ Therapeutics, Inc. (NASDAQ:LENZ ) Q4 2024 Results Conference Call March 19, 2025 4:30 PM ET Company Participants Dan Chevallard - Chief Financial Officer Eef Schimmelpennink - President & Chief Executive Officer Shawn Olsson - Chief Commercial Officer Marc Odrich - Chief Medical Officer Conference Call Participants Yigal Nochomovitz - Citigroup Madhu Yennawar - Leerink Partners Joe Catanza...
Neutral
GlobeNewsWire
about one month ago
New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025
Neutral
GlobeNewsWire
about 2 months ago
SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced it will host a webcast on Wednesday, March 19, 2025, at 4:30 p.m. EST to...
Neutral
GlobeNewsWire
about 2 months ago
SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that it will host a Commercial Day to highlight the commercialization st...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today